

# Nicholas J Maragakis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5894797/publications.pdf>

Version: 2024-02-01

87  
papers

8,706  
citations

66315

42  
h-index

54882

84  
g-index

91  
all docs

91  
docs citations

91  
times ranked

10927  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human induced pluripotent stem cell-derived astrocytes progenitors as discovery platforms. , 2022, , 45-89.		0
2	Exploring Motor Neuron Diseases Using iPSC Platforms. Stem Cells, 2022, 40, 2-13.	1.4	6
3	Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPSC cells. Molecular Neurodegeneration, 2022, 17, 8.	4.4	10
4	Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nature Neuroscience, 2022, 25, 226-237.	7.1	66
5	Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2107391119.	3.3	29
6	Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 186.	4.5	79
7	Mini-Review: Induced pluripotent stem cells and the search for new cell-specific ALS therapeutic targets. Neuroscience Letters, 2021, 755, 135911.	1.0	20
8	Association of Variants in the <i>SPTLC1</i> Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	4.5	46
9	Establishment of an Electrophysiological Platform for Modeling ALS with Regionally-Specific Human Pluripotent Stem Cell-Derived Astrocytes and Neurons. Journal of Visualized Experiments, 2021, , .	0.2	5
10	Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 821-831.	4.9	9
11	MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. Neurodegenerative Disease Management, 2021, 11, 431-443.	1.2	16
12	Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS. Nature Neuroscience, 2021, 24, 1673-1685.	7.1	38
13	Focal and dose-dependent neuroprotection in ALS mice following AAV2-neurturin delivery. Experimental Neurology, 2020, 323, 113091.	2.0	9
14	Primary lateral sclerosis (PLS) functional rating scale: PLS-specific clinimetric scale. Muscle and Nerve, 2020, 61, 163-172.	1.0	17
15	Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle and Nerve, 2020, 62, 156-166.	1.0	60
16	Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients. Journal of Neuropathology and Experimental Neurology, 2020, 79, 266-276.	0.9	17
17	Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities. Muscle and Nerve, 2020, 62, 182-186.	1.0	42
18	Role of Human-Induced Pluripotent Stem Cell-Derived Spinal Cord Astrocytes in the Functional Maturation of Motor Neurons in a Multielectrode Array System. Stem Cells Translational Medicine, 2019, 8, 1272-1285.	1.6	34

#	ARTICLE	IF	CITATIONS
19	Analyzing progression of motor and speech impairment in ALS. , 2019, 2019, 6097-6102.		5
20	Perfluorocarbon Labeling of Human Glial-Restricted Progenitors for 19F Magnetic Resonance Imaging. Stem Cells Translational Medicine, 2019, 8, 355-365.	1.6	11
21	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	3.8	517
22	A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 250-258.	1.1	44
23	Olfactory dysfunction in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 976-981.	1.7	28
24	Current and emerging ALS biomarkers: utility and potential in clinical trials. Expert Review of Neurotherapeutics, 2018, 18, 871-886.	1.4	18
25	A stocked toolbox for understanding the role of astrocytes in disease. Nature Reviews Neurology, 2018, 14, 351-362.	4.9	53
26	Motor neuron-derived microRNAs cause astrocyte dysfunction in amyotrophic lateral sclerosis. Brain, 2018, 141, 2561-2575.	3.7	50
27	Serial in vivo imaging of transplanted allogeneic neural stem cell survival in a mouse model of amyotrophic lateral sclerosis. Experimental Neurology, 2017, 289, 96-102.	2.0	11
28	Defining SOD1 ALS natural history to guide therapeutic clinical trial design. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 99-105.	0.9	68
29	MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models. Journal of Neuroscience, 2017, 37, 5574-5586.	1.7	66
30	Sporadic ALS Astrocytes Induce Neuronal Degeneration In Vivo. Stem Cell Reports, 2017, 8, 843-855.	2.3	105
31	What can we learn from the edaravone development program for ALS?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 98-103.	1.1	15
32	Motoneuron Disease: Basic Science. Advances in Neurobiology, 2017, 15, 163-190.	1.3	5
33	Motoneuron Disease: Clinical. Advances in Neurobiology, 2017, 15, 191-210.	1.3	2
34	Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients. Molecular Neurodegeneration, 2017, 12, 76.	4.4	49
35	Erratum. Advances in Neurobiology, 2017, 15, E1-E1.	1.3	1
36	Astrocytes drive upregulation of the multidrug resistance transporter ABCB1 (P-glycoprotein) in endothelial cells of the blood-brain barrier in mutant superoxide dismutase 1-linked amyotrophic lateral sclerosis. Glia, 2016, 64, 1298-1313.	2.5	57

#	ARTICLE	IF	CITATIONS
37	Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model. <i>Cell Reports</i> , 2016, 15, 2301-2312.	2.9	141
38	Primary Lateral Sclerosis and Early Upper Motor Neuron Disease. <i>Journal of Clinical Neuromuscular Disease</i> , 2016, 17, 99-105.	0.3	17
39	Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis. <i>Glia</i> , 2016, 64, 1154-1169.	2.5	114
40	Generation of <sc>GFAP::GFP</sc> astrocyte reporter lines from human adult fibroblastâ€ derived i<sc>PS</sc> cells using zincâ€ finger nuclease technology. <i>Glia</i> , 2016, 64, 63-75.	2.5	26
41	A Spontaneous Missense Mutation in Branched Chain Keto Acid Dehydrogenase Kinase in the Rat Affects Both the Central and Peripheral Nervous Systems. <i>PLoS ONE</i> , 2016, 11, e0160447.	1.1	16
42	Hemiparetic Primary Lateral Sclerosis: Revisiting Mills Syndrome. <i>Case Reports in Neurology</i> , 2015, 7, 191-195.	0.3	7
43	Preâ€ morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2015, 52, 339-343.	1.0	25
44	A Comprehensive Library of Familial Human Amyotrophic Lateral Sclerosis Induced Pluripotent Stem Cells. <i>PLoS ONE</i> , 2015, 10, e0118266.	1.1	45
45	Human glial progenitor engraftment and gene expression is independent of the ALS environment. <i>Experimental Neurology</i> , 2015, 264, 188-199.	2.0	21
46	Neural and glial progenitor transplantation as a neuroprotective strategy for Amyotrophic Lateral Sclerosis (ALS). <i>Brain Research</i> , 2015, 1628, 343-350.	1.1	39
47	Human iPSC cell-derived astrocyte transplants preserve respiratory function after spinal cord injury. <i>Experimental Neurology</i> , 2015, 271, 479-492.	2.0	61
48	Transplantation of Glial Progenitors That Overexpress Glutamate Transporter GLT1 Preserves Diaphragm Function Following Cervical SCI. <i>Molecular Therapy</i> , 2015, 23, 533-548.	3.7	35
49	Induced pluripotent stem cells from ALS patients for disease modeling. <i>Brain Research</i> , 2015, 1607, 15-25.	1.1	57
50	C9orf72 nucleotide repeat structures initiate molecular cascades of disease. <i>Nature</i> , 2014, 507, 195-200.	13.7	779
51	Electrical impedance myography correlates with standard measures of Als severity. <i>Muscle and Nerve</i> , 2014, 49, 441-443.	1.0	61
52	Gene Profiling of Human Induced Pluripotent Stem Cell-Derived Astrocyte Progenitors Following Spinal Cord Engraftment. <i>Stem Cells Translational Medicine</i> , 2014, 3, 575-585.	1.6	37
53	RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention. <i>Neuron</i> , 2013, 80, 415-428.	3.8	785
54	Altered astrocytic expression of TDP-43 does not influence motor neuron survival. <i>Experimental Neurology</i> , 2013, 250, 250-259.	2.0	49

#	ARTICLE	IF	CITATIONS
55	Multimodal Actions of Neural Stem Cells in a Mouse Model of ALS: A Meta-Analysis. <i>Science Translational Medicine</i> , 2012, 4, 165ra164.	5.8	91
56	Glia: an emerging target for neurological disease therapy. <i>Stem Cell Research and Therapy</i> , 2012, 3, 37.	2.4	24
57	Electrical impedance myography as a biomarker to assess ALS progression. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012, 13, 439-445.	2.3	125
58	Sciatic nerve tumor and tumor-like lesionsâ€”uncommon pathologies. <i>Skeletal Radiology</i> , 2012, 41, 763-774.	1.2	55
59	Human Glial-Restricted Progenitor Transplantation into Cervical Spinal Cord of the SOD1G93A Mouse Model of ALS. <i>PLoS ONE</i> , 2011, 6, e25968.	1.1	107
60	Spatial and temporal changes in promoter activity of the astrocyte glutamate transporter GLT1 following traumatic spinal cord injury. <i>Journal of Neuroscience Research</i> , 2011, 89, 1001-1017.	1.3	35
61	Reduction in expression of the astrocyte glutamate transporter, GLT1, worsens functional and histological outcomes following traumatic spinal cord injury. <i>Glia</i> , 2011, 59, 1996-2005.	2.5	48
62	New Treatments in Amyotrophic Lateral Sclerosis. <i>Neuropsychopharmacology</i> , 2011, 36, 370-372.	2.8	1
63	Astrocytes carrying the superoxide dismutase 1 (SOD1 <sup>G93A</sup> ) mutation induce wild-type motor neuron degeneration in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 17803-17808.	3.3	194
64	Stem Cell Transplantation for Spinal Cord Neurodegeneration. <i>Methods in Molecular Biology</i> , 2011, 793, 479-493.	0.4	6
65	Peripheral hyperstimulation alters site of disease onset and course in SOD1 rats. <i>Neurobiology of Disease</i> , 2010, 39, 252-264.	2.1	36
66	Stem cells and the ALS neurologist. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 417-423.	2.3	15
67	Advances in stem cell research for Amyotrophic Lateral Sclerosis. <i>Current Opinion in Biotechnology</i> , 2009, 20, 545-551.	3.3	45
68	Rethinking a drug treatment failure on a traditional ALS target. <i>Experimental Neurology</i> , 2009, 216, 254-257.	2.0	1
69	Adult glial precursor proliferation in mutant SOD1 <sup>G93A</sup> mice. <i>Glia</i> , 2008, 56, 200-208.	2.5	81
70	Focal transplantationâ€”based astrocyte replacement is neuroprotective in a model of motor neuron disease. <i>Nature Neuroscience</i> , 2008, 11, 1294-1301.	7.1	403
71	Protective Role of Reactive Astrocytes in Brain Ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 468-481.	2.4	441
72	Selective ablation of proliferating astrocytes does not affect disease outcome in either acute or chronic models of motor neuron degeneration. <i>Experimental Neurology</i> , 2008, 211, 423-432.	2.0	77

#	ARTICLE	IF	CITATIONS
73	Impaired SDF1/CXCR4 signaling in glial progenitors derived from SOD1G93A mice. <i>Journal of Neuroscience Research</i> , 2007, 85, 2422-2432.	1.3	19
74	Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. <i>Brain Research</i> , 2007, 1185, 256-265.	1.1	112
75	Mechanisms of Disease: astrocytes in neurodegenerative disease. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 679-689.	2.7	700
76	Loss of the astrocyte glutamate transporter GLT1 modifies disease in SOD1G93A mice. <i>Experimental Neurology</i> , 2006, 201, 120-130.	2.0	113
77	Degeneration of respiratory motor neurons in the SOD1 G93A transgenic rat model of ALS. <i>Neurobiology of Disease</i> , 2006, 21, 110-118.	2.1	63
78	Recovery from paralysis in adult rats using embryonic stem cells. <i>Annals of Neurology</i> , 2006, 60, 32-44.	2.8	266
79	Glial restricted precursors protect against chronic glutamate neurotoxicity of motor neurons in vitro. <i>Glia</i> , 2005, 50, 145-159.	2.5	40
80	Viral-Induced Spinal Motor Neuron Death Is Non-Cell-Autonomous and Involves Glutamate Excitotoxicity. <i>Journal of Neuroscience</i> , 2004, 24, 7566-7575.	1.7	96
81	Altered expression of the glutamate transporter EAAT2b in neurological disease. <i>Annals of Neurology</i> , 2004, 55, 469-477.	2.8	122
82	Glutamate transporter expression and function in human glial progenitors. <i>Glia</i> , 2004, 45, 133-143.	2.5	74
83	Glutamate transporters: animal models to neurologic disease. <i>Neurobiology of Disease</i> , 2004, 15, 461-473.	2.1	321
84	Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice. <i>Neuroscience Letters</i> , 2003, 338, 107-110.	1.0	48
85	Human Embryonic Germ Cell Derivatives Facilitate Motor Recovery of Rats with Diffuse Motor Neuron Injury. <i>Journal of Neuroscience</i> , 2003, 23, 5131-5140.	1.7	239
86	Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 1604-1609.	3.3	766
87	Amyotrophic Lateral Sclerosis: Pathogenesis, Differential Diagnoses, And Potential Interventions. <i>Journal of Spinal Cord Medicine</i> , 2002, 25, 262-273.	0.7	12